Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Rapid assessment of the osteogenic capacity of hydroxyapatite/aragonite using a murine tibial periosteal ossification model.

Steijvers E. et al, (2025), Bioact mater, 45, 257 - 273

Introduction to the Bisphosphonate Special Issue.

Eastell R. and Russell RGG., (2023), Bone, 172

In vitro and in vivo effects of zoledronic acid on senescence and senescence-associated secretory phenotype markers.

Samakkarnthai P. et al, (2023), Aging (albany ny), 15, 3331 - 3355

In vitroandin vivoeffects of zoledronate on senescence and senescence-associated secretory phenotype markers

Samakkarnthai P. et al, (2023)

Real-Time Impedance-Based Monitoring of the Growth and Inhibition of Osteomyelitis Biofilm Pathogen Staphylococcus aureus Treated with Novel Bisphosphonate-Fluoroquinolone Antimicrobial Conjugates.

Sedghizadeh PP. et al, (2023), Int j mol sci, 24

Bisphosphonates: The role of chemistry in understanding their biological actions and structure-activity relationships, and new directions for their therapeutic use.

Ebetino FH. et al, (2022), Bone, 156

Towards a cure for osteoporosis: the UK Royal Osteoporosis Society (ROS) Osteoporosis Research Roadmap.

Harvey NC. et al, (2022), Arch osteoporos, 17

Foreword I

(2022), Bone Cancer, xxiii - xxiv

Bisphosphonates in dentistry: Historical perspectives, adverse effects, and novel applications.

Sedghizadeh PP. et al, (2021), Bone, 147

Advances in the molecular pharmacology of bone and cancer-related bone diseases.

Edwards CM. and Russell RGG., (2021), Br j pharmacol, 178, 1889 - 1890

Bisphosphonates for delivering drugs to bone.

Sun S. et al, (2021), Br j pharmacol, 178, 2008 - 2025

Real-time impedance-based monitoring of the growth and inhibition of osteomyelitis pathogen Staphylococcus aureus biofilms treated with novel bisphosphonate-fluoroquinolone antimicrobial conjugates

Sedghizadeh P. et al, (2020), Bone reports, 13, 100580 - 100580

History of alendronate.

Cummings SR. et al, (2020), Bone, 137

Zoledronate.

Reid IR. et al, (2020), Bone, 137

Differences in intracellular localisation of ANKH mutants that relate to mechanisms of calcium pyrophosphate deposition disease and craniometaphyseal dysplasia.

Vijen S. et al, (2020), Sci rep, 10

Clinical and translational pharmacology of bisphosphonates

Cremers S. et al, (2020), Principles of Bone Biology, 1671 - 1687

Clinical Guidelines on Paget's Disease of Bone.

Ralston SH. et al, (2019), J bone miner res, 34, 2327 - 2329

Zoledronate in the prevention of Paget's (ZiPP): protocol for a randomised trial of genetic testing and targeted zoledronic acid therapy to prevent SQSTM1-mediated Paget's disease of bone.

Cronin O. et al, (2019), Bmj open, 9

Drugs for the treatment of metabolic bone diseases.

Drake MT. et al, (2019), Br j clin pharmacol, 85, 1049 - 1051

Pharmacology of bisphosphonates.

Cremers S. et al, (2019), Br j clin pharmacol, 85, 1052 - 1062

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?